




(86) **Date de dépôt PCT/PCT Filing Date:** 2010/02/26
(87) **Date publication PCT/PCT Publication Date:** 2010/09/02
(45) **Date de délivrance/Issue Date:** 2014/01/07
(85) **Entrée phase nationale/National Entry:** 2011/08/24
(86) **N° demande PCT/PCT Application No.:** CN 2010/070780
(87) **N° publication PCT/PCT Publication No.:** 2010/097052
(30) **Priorité/Priority:** 2009/02/27 (CN200910046782.1)

(51) **Cl.Int./Int.Cl. C07C 231/12** (2006.01),
C07C 233/18 (2006.01)
(72) **Inventeurs/Inventors:**
ZHANG, PENG, CN;
SHAN, HANBIN, CN;
YUAN, ZHEDONG, CN;
JIANG, XUDONG, CN;
HUANG, YU, CN;
WANG, HUBO, CN;
CAO, XUFENG, CN;
...
(73) **Propriétaire/Owner:**
LES LABORATOIRES SERVIERS, FR
(74) **Agent:** NORTON ROSE FULBRIGHT CANADA

(54) **Titre : COMPLEXE D'HYDROHALOGENURE D'AGOMELATINE ET PROCEDE DE PREPARATION DE CELUI-CI**
(54) **Title: AGOMELATINE HYDROHALIDE COMPLEX AND PREPARATION METHOD THEREOF**



(57) **Abrégé/Abstract:**

Agomelatine hydrohalide complex and preparation method thereof are disclosed. Compared with agomelatine, agomelatine hydrohalide complex obtained by the present method has improved solubility, and is suitable for application need of preparation of finished products of drugs. Furthermore, the product has good stability and high purity. The preparation process is simple and convenient, and the product with high purity can be obtained without special operations.



(72) **Inventeurs(suite)/Inventors(continued)**: CHENG, XINGDONG, CN; PAN, HONGJUAN, CN; YU, XIONG, CN

(74) **Agent(suite/continued)**: LLP/S.E.N.C.R.L., S.R.L.

(12) 按照专利合作条约所公布的国际申请

(19) 世界知识产权组织
国际局(43) 国际公布日
2010年9月2日 (02.09.2010)(10) 国际公布号
WO 2010/097052 A1

- (51) 国际专利分类号:
C07C 231/12 (2006.01) C07C 233/18 (2006.01)
- (21) 国际申请号: PCT/CN2010/070780
- (22) 国际申请日: 2010年2月26日 (26.02.2010)
- (25) 申请语言: 中文
- (26) 公布语言: 中文
- (30) 优先权:
200910046782.1 2009年2月27日 (27.02.2009) CN
- (71) 申请人 (对除美国外的所有指定国): 上海医药工业研究院 (SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。
- (72) 发明人: 及
- (75) 发明人/申请人 (仅对美国): 张鹏 (ZHANG, Peng) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。 单汉滨 (SHAN, Hanbin) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。 袁哲东 (YUAN, Zhedong) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。 蒋旭东 (JIANG, Xudong) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。 黄雨 (HUANG, Yu) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。 王胡博 (WANG, Hubo) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。 曹旭峰 (CAO, Xufeng) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。 程兴栋 (CHENG, Xingdong) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。 潘红娟 (PAN, Hongjuan) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200437 (CN)。 俞雄 (YU, Xiong) [CN/CN]; 中国上海市北京西路1320号, Shanghai 200040 (CN)。
- (74) 代理人: 上海金盛协力知识产权代理有限公司 (SHANGHAI CO-EFFORT IPR AGENT CO., LTD.); 中国上海市陆家嘴环路958号华能联合大厦31楼, Shanghai 200120 (CN)。
- (81) 指定国 (除另有指明, 要求每一种可提供的国家保护): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW。
- (84) 指定国 (除另有指明, 要求每一种可提供的地区保护): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), 欧亚 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), 欧洲 (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)。
- 根据细则 4.17 的声明:
— 发明人资格(细则 4.17(iv))
- 本国际公布:
— 包括国际检索报告(条约第 21 条(3))。

(54) Title: AGOMELATINE HYDROHALIDE COMPLEX AND PREPARATION METHOD THEREOF

(54) 发明名称: 阿戈美拉汀卤化氢复合物及其制备方法

(57) Abstract: Agomelatine hydrohalide complex and preparation method thereof are disclosed. Compared with agomelatine, agomelatine hydrohalide complex obtained by the present method has improved solubility, and is suitable for application need of preparation of finished products of drugs. Furthermore, the product has good stability and high purity. The preparation process is simple and convenient, and the product with high purity can be obtained without special operations.

(57) 摘要:

本发明公开了阿戈美拉汀卤化氢复合物及其制备方法。本发明方法得到的阿戈美拉汀卤化氢复合物, 溶解性比阿戈美拉汀有提高, 适合成品药物制剂时的应用需要; 且产品稳定性好、纯度高。在制备工艺上简便, 无需特殊的操作, 即可得到高纯度的产品。

WO 2010/097052 A1


Agomelatine Hydrohalide Complex and Preparation Method Thereof

Technical field

The present invention relates to a complex of agomelatine and to preparation thereof.

Technical Background

The structure of agomelatine (1), with the chemical name N-[2-(7-methoxy-1-naphthyl)ethyl]-acetamide, is shown by the formula II below. It is marketed under the trademark name of Valdoxan by the French company Servier as a melatonin agonist and antagonist of the 5HT_{2C} receptor, for the treatment of depression, sleep enhancement and maintenance of sexual function.



In view of its pharmaceutical value, it is important then to be able to produce the compound or a complex thereof with better purity, solubility and more reproducible performance.


Summary of the Invention

The objective of the present invention is to provide a hydrogen halide complex of agomelatine, which is more soluble, more stable, and of higher purity, making it more suitable to be used in pharmaceutical preparations containing agomelatine. A further objective of the

present invention is to provide a preparation method for the said hydrogen halide complex of agomelatine.

When the present inventors attempted to purify agomelatine product, they surprisingly found that agomelatine can form a physically and chemically stable complex when mixed with inorganic acids such as hydrochloric acid (HCl), hydrobromic acid (HBr), and hydroiodic acid (HI). The said complex is suitable for the preparation of pharmaceutical compositions. However, when other conventional inorganic acids (such as sulphuric acid, phosphoric acid, perchloric acid) or organic acids (such as acetic acid, oxalic acid, tartaric acid, fumaric acid) were used, it was not easy to produce the complex.

The said hydrogen halide complex of agomelatine has the following structure:



wherein X is halogen, preferably Cl or Br.

The present invention provides a preparation method for the said hydrogen halide complex of agomelatine, wherein agomelatine is reacted with HX in any form to produce the complex. In the process, agomelatine can be dissolved in an organic solvent before HX is bubbled in and the precipitated crystal is rinsed and dried; alternatively, agomelatine can be added to an organic solution containing HX and the precipitated crystal is rinsed and dried. The concentration of HX should be the minimal required for precipitation of the complex. The results from many experiments showed that HCl in ethyl acetate (HCl/EtOAc) produces the complex with the highest yield. Therefore, the most preferred method is to add agomelatine to the solution of HCl in EtOAc to allow the target product to crystallise, which is then rinsed and dried.

In the present method of preparing hydrogen halide complexes of agomelatine, there is no restriction on the organic solvent used as long as it is able to dissolve the reactants, agomelatine and HX, and allows the precipitation of the complex. The said solvent may be selected from ethyl acetate, methyl acetate, n-butyl acetate, acetone, acetonitrile and the like, ethyl acetate being the most preferred. However, low-polarity solvents such as alcohols (ethanol and methanol etc.), DMF, DMSO are not suitable.

Benefits of this invention

The present invention is advantageous in that the inventors found that among so many conventional acids, agomelatine can only react with hydrogen halide to form a stable complex, the physical properties of which, such as stability, solubility, and hygroscopicity, are better than those products of agomelatine with any other acid. The process is also less complicated than if other acids were used.

The hydrogen halide complex of agomelatine produced according to the present method is more soluble, more stable, and of higher purity than agomelatine itself, making it more suitable to be used in pharmaceutical preparations. In addition, a product of high purity can be obtained through a simple process, without having to incur further complicated steps.

Content of the Invention

The following examples are designed to further illustrate the present invention, wherein the specific parameters and steps are not intended to limit the required scope of protection of the present invention.

Example 1:

1.0 g of agomelatine was dissolved in 10 ml of EtOAc with stirring, dry HCl gas was bubbled through the solution slowly at room temperature until the solution stopped gaining weight. The mixture was then filtered, the solid washed twice with 2 ml of EtOAc and dried at 30°C to yield 1.05 g of white solid (purity: 99.7%).

Analytical results: (C₁₅H₁₇NO₂•HCl)

Calculated: Cl% (12.69%)

Found: Cl% (12.44%)

Melting point: 64-66°C

Example 2:

3.0 g of agomelatine was dissolved in 30 ml of EtOAc with stirring, dry HCl gas was bubbled through the solution at room temperature until the solution stopped gaining weight. The mixture was then filtered, the solid washed twice with 5 ml of EtOAc and dried at 30°C to yield 3.2 g of white solid (purity: 99.8%).

Analytical results: (C₁₅H₁₇NO₂•HCl)

Calculated: Cl% (12.69%)

Found: Cl% (12.60%)

Melting point: 64-66°C

Example 3:

10 g of agomelatine was dissolved in 100 ml of EtOAc with stirring, dry HCl gas was bubbled through the solution at room temperature until the solution stopped gaining weight. The mixture was then filtered, the solid washed twice with 10 ml of EtOAc and dried at 30°C to yield 10.8 g of white solid (purity: 99.8%).

Analytical results: (C₁₅H₁₇NO₂•HCl)

Calculated: Cl% (12.69%)

Found: Cl% (12.21%)

Melting point: 64-66°C

Example 4:

10 g of agomelatine was added to 100 ml of EtOAc solution saturated with HCl gas. The mixture was stirred for 1h at room temperature and then filtered, the solid washed twice with 10 ml of EtOAc and dried at 30°C to yield 10.9 g of white solid (purity: 99.8%).

Analytical results: (C₁₅H₁₇NO₂•HCl)

Calculated: Cl% (12.69%)

Found: Cl% (12.39%)

Melting point: 64-66°C

Example 5:

According to the method for preparing agomelatine disclosed in Chinese Patent CN1680284A, a solution of 17.3 g of 2-(7-methoxy-1-naphthyl)ethylamine hydrochloride and 6.6 g sodium acetate in ethanol was added to a reactor, then 7.9 g of acetic anhydride was added with stirring. The mixture was heated to reflux and then 60 ml of water was added. The mixture was cooled down to room temperature and the solid was filtered off. The filtrate was extracted three times with 20 ml of EtOAc and the combined extracts were evaporated to dryness. The obtained solid was then dissolved in 100 ml of EtOAc with stirring; dry HCl gas was bubbled through the solution at room temperature until the solution stopped gaining weight. The mixture was then filtered, the solid washed twice with 10 ml of EtOAc and dried at 30°C to yield 18.5 g of white solid (yield: 91%; purity: 99.1%).

Analytical results: (C₁₅H₁₇NO₂•HCl)

Calculated: Cl% (12.69%)

Found: Cl% (12.57%)

Melting point: 64-66°C

Example 6:

According to the method for preparing agomelatine disclosed in Chinese Patent CN1680284A, a solution of 17.3 g of 2-(7-methoxy-1-naphthyl) ethylamine hydrochloride and

6.6 g sodium acetate in ethanol was added to a reactor, then 7.9 g of acetic anhydride was added with stirring. The mixture was heated to reflux and then 60 ml of water was added. The mixture was cooled down to room temperature and the solid was filtered off. The filtrate was extracted three times with 20 ml of EtOAc and the combined extracts were evaporated to dryness. The obtained solid was then added to 100 ml of EtOAc solution saturated with HCl gas and stirred for 1h at room temperature. The mixture was then filtered, the solid washed twice with 10 ml of EtOAc and dried at 30°C to yield 18.7 g of white solid (yield: 92%; purity: 99.8%).

Analytical results: (C₁₅H₁₇NO₂•HCl)

Calculated: Cl% (12.69%)

Found: Cl% (12.70%)

Melting point: 64-66°C

Example 7:

10 g of agomelatine was dissolved in 100 ml of EtOAc with stirring, and dry HBr gas was bubbled through the solution at room temperature until it stopped gaining weight. The mixture was then filtered, the solid washed twice with 10 ml of EtOAc and dried at 30°C to yield 11.2 g of white solid (purity: 99.3%).

Analytical results: (C₁₅H₁₇NO₂•HCl)

Calculated: Br% (24.6%)

Found: Br% (23.8%)

Melting point: 85-87°C

Example 8:

1 g of agomelatine was dissolved in 10 ml of EtOAc with stirring, and concentrated H₂SO₄ was added dropwise at room temperature. No solid precipitated during the entire process.

Example 9:

1 g of agomelatine was dissolved in 10 ml of EtOAc with stirring, and concentrated H₂SO₄ was added dropwise at -10°C. No solid precipitated during the entire process.

Example 10:

1 g of agomelatine was dissolved in 10 ml of EtOAc with stirring, and glacial acetic acid was added dropwise at -10°C. No solid precipitated during the entire process.

Example 11:

1 g of agomelatine was dissolved in 10 ml of EtOAc with stirring, and fumaric acid was added dropwise at -10°C. No solid precipitated during the entire process.

Detection Method

The complex of agomelatine with HCl and HBr were both placed in an incubator at 40°C for 30 days. Afterwards, the stability of these crystals was studied using HPLC.

1. Purity determination

HPLC conditions: C18 column; mobile phase: 10 mM/L phosphate buffer (adjusted to pH 7.0 with NaOH) : acetonitrile = 2 : 7 (v/v); column temperature: 40°C; detection wavelength: 220 nm; the internal standard method was used.

The products were each dissolved in the mobile phase at 1 mg/mL. 10 µL was injected into the chromatograph and chromatograms were recorded.

2. Content determination

The same method was used for the purity test, except that an external standard was used. The results are shown in the table below:

Table 1

Agomelatine Complex	Day 0	Day 5	Day 10	Day 30
Agomelatine·HCl	99.8%	99.8%	99.8%	99.8%
Agomelatine·HBr	99.3%	99.3%	99.3%	99.3%

3. Water Solubility


HPLC with external standard was used in the analysis. The results are shown below.

Table 2

Sample	Agomelatine	Agomelatine·HBr	Agomelatine·HCl
Purity	99.79%	99.77%	99.82%
Solubility (mg/ml)	1.11	2.14	1.60

CLAIMS

1. A hydrogen halide complex of agomelatine, which has the following structure:



wherein X is halogen.

2. The hydrogen halide complex of agomelatine according to claim 1, wherein X is Cl or Br.

3. A method for the preparation of the hydrogen halide complex of agomelatine according to claim 1 or 2, wherein agomelatine is reacted with HX in any form to produce the complex.

4. The method for the preparation of the hydrogen halide complex of agomelatine according to claim 3, wherein agomelatine is dissolved in an organic solvent to form a solution before HX gas is bubbled through and the complex is precipitated.

5. The method for the preparation of the hydrogen halide complex of agomelatine according to claim 3, wherein agomelatine is added to an organic solution containing HX before the complex is precipitated.

6. The method for the preparation of the hydrogen halide complex of agomelatine according to claim 4, wherein HX gas is bubbled through until the solution is saturated.

